Editas Medicine, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 40.29 million compared to USD 53.45 million a year ago. Basic loss per share from continuing operations was USD 0.56 compared to USD 0.78 a year ago.
For the six months, net loss was USD 89.33 million compared to USD 103.97 million a year ago. Basic loss per share from continuing operations was USD 1.27 compared to USD 1.52 a year ago.